Fortis Healthcare Limited (FORTIS.NS) Bundle
As Fortis Healthcare's FY25 results reveal a mix of momentum and leverage that every investor should dissect, consolidated revenue climbed 12.9% to ₹7,783 crore with hospital revenue up 14.8% to ₹6,528 crore and Q1 FY26 revenue surging 16.6% to ₹2,167 crore, while profitability improved - EBITDA margin expanded to 20.4% (hospital EBITDA 20.5%, diagnostic EBITDA 22.0%) and PAT rose 25.4% to ₹809 crore (EPS ₹10.26) even as net debt ballooned from ₹264 crore to ₹1,694 crore after raising ₹1,550 crore via NCDs to consolidate Agilus to 89.20%; juxtapose that balance-sheet shift with valuation metrics - market cap at ₹659.87 billion, stock at ₹874.05 (52-week ₹577-₹1,104.30) and a P/E of 85.19 (forward 47.39) - and you have critical trade-offs between growth (2,000-bed expansion, Shrimann acquisition, diagnostic consolidation) and risks (higher leverage, integration, regulatory pressure, patient-volume variability) that demand a close read of the full breakdown to weigh upside versus exposure
Fortis Healthcare Limited (FORTIS.NS) - Revenue Analysis
Fortis reported notable revenue expansion across FY25 and early FY26, led by hospital operations and specialty services.
- Consolidated revenue rose 12.9% YoY to ₹7,783 crore in FY25 (from ₹6,893 crore in FY24).
- Hospital business revenue increased 14.8% YoY to ₹6,528 crore in FY25 (from ₹5,686 crore in FY24).
- Diagnostic business (net) revenue grew 4.0% YoY to ₹1,255 crore in FY25 (from ₹1,207 crore in FY24).
- Hospital business contributed 84% to consolidated revenue in FY25 (up from 82% in FY24).
- Revenue from focus specialties expanded 16% YoY and accounted for 62% of overall hospital revenues in FY25.
- In Q1 FY26, consolidated revenue was ₹2,167 crore, up 16.6% from ₹1,859 crore in Q1 FY25.
| Metric | FY24 | FY25 | YoY Change |
|---|---|---|---|
| Consolidated Revenue (₹ crore) | 6,893 | 7,783 | +12.9% |
| Hospital Business Revenue (₹ crore) | 5,686 | 6,528 | +14.8% |
| Diagnostic Business Revenue - Net (₹ crore) | 1,207 | 1,255 | +4.0% |
| Hospital Contribution to Consolidated Revenue | 82% | 84% | +2 pp |
| Focus Specialties Contribution to Hospital Revenue | (not disclosed) | 62% | +16% YoY growth in revenue from focus specialties |
| Q1 FY25 Consolidated Revenue (₹ crore) | 1,859 | - | - |
| Q1 FY26 Consolidated Revenue (₹ crore) | - | 2,167 | +16.6% vs Q1 FY25 |
- Drivers: stronger inpatient/outpatient throughput in hospitals and higher share of high-margin focus specialties.
- Diagnostics growth was modest relative to hospitals, indicating potential upside from scaling network utilization or pricing.
- Quarterly momentum (Q1 FY26) suggests acceleration vs FY25 run-rate.
Exploring Fortis Healthcare Limited Investor Profile: Who's Buying and Why?
Fortis Healthcare Limited (FORTIS.NS) Profitability Metrics
Fortis Healthcare delivered meaningful margin expansion and earnings growth in FY25, driven by stronger hospital operations and a recovery in diagnostics (adjusted for one-offs). Key headline figures reflect improved operating leverage and higher PAT and EPS.- EBITDA margin (consolidated) improved to 20.4% in FY25 from 18.4% in FY24.
- Hospital business EBITDA margin rose to 20.5% in FY25 (vs 18.6% in FY24).
- Diagnostic business EBITDA margin (excluding one-offs) reached 22.0% in FY25, up from 19.6% in FY24.
- Operating EBITDA margin in Q1 FY26 was 22.6%, compared with 18.4% in Q1 FY25.
- Profit after tax (PAT) was ₹809 crore in FY25, a 25.4% increase from ₹645 crore in FY24.
- Earnings per share (EPS) increased to ₹10.26 in FY25 from ₹7.93 in FY24.
| Metric | FY24 | FY25 | YoY Change |
|---|---|---|---|
| Consolidated EBITDA Margin | 18.4% | 20.4% | +2.0 ppt |
| Hospital EBITDA Margin | 18.6% | 20.5% | +1.9 ppt |
| Diagnostics EBITDA Margin (ex one-offs) | 19.6% | 22.0% | +2.4 ppt |
| Operating EBITDA Margin (Q1) | Q1 FY25: 18.4% | Q1 FY26: 22.6% | +4.2 ppt |
| Profit After Tax (PAT) | ₹645 crore | ₹809 crore | +25.4% |
| Earnings Per Share (EPS) | ₹7.93 | ₹10.26 | +29.4% |
Fortis Healthcare Limited (FORTIS.NS) - Debt vs. Equity Structure
Fortis Healthcare's capital structure shifted notably in FY25 as the company increased leverage to fund strategic consolidation of Agilus Diagnostics Ltd. Key headline numbers show a material rise in both gross and net debt, with leverage ratios rising from relatively low levels in FY24.- Net debt rose to ₹1,694 crore as of March 31, 2025, up from ₹264 crore on March 31, 2024.
- Gross debt increased to ₹2,196 crore as of March 31, 2025, versus ₹859 crore as of March 31, 2024.
- Net debt-to-equity moved from 0.18x in FY24 to 0.25x in FY25.
- Net debt-to-EBITDA jumped to 0.93x in FY25 from 0.17x in FY24.
- The company raised ₹1,550 crore via Non-Convertible Debentures (NCDs) in FY25.
- Incremental debt was primarily used to consolidate Fortis' stake in Agilus Diagnostics Ltd. to 89.20%.
| Metric | As of Mar 31, 2024 | As of Mar 31, 2025 | Change |
|---|---|---|---|
| Gross Debt (₹ crore) | 859 | 2,196 | +1,337 |
| Net Debt (₹ crore) | 264 | 1,694 | +1,430 |
| Net Debt-to-Equity (x) | 0.18 | 0.25 | +0.07 |
| Net Debt-to-EBITDA (x) | 0.17 | 0.93 | +0.76 |
| Funds raised via NCDs (₹ crore) | - | 1,550 | +1,550 |
| Stake in Agilus Diagnostics | Prior to consolidation | 89.20% | Consolidated via debt-funded acquisition |
- Implication: the rise in gross and net debt reflects a deliberate financing decision-largely NCD-driven-to consolidate Agilus, increasing leverage metrics though absolute ratios remain modest relative to many leveraged corporates.
- Liquidity and servicing: with Net debt-to-EBITDA at 0.93x in FY25, interest coverage and cash flow conversion will be the focus for monitoring near-term leverage sustainability.
- Related reading: Fortis Healthcare Limited: History, Ownership, Mission, How It Works & Makes Money
Fortis Healthcare Limited (FORTIS.NS) - Liquidity and Solvency
Fortis Healthcare reported meaningful improvement in operating profitability alongside a rise in leverage in FY25. Operating EBITDA margins expanded while profitability (PAT and EPS) strengthened; however, net debt increased materially due to financing activity, raising the net debt-to-EBITDA ratio.- Operating EBITDA margin: 18.4% in FY24 → 20.4% in FY25 (improvement reflects better cost absorption and revenue mix).
- Quarterly momentum: Operating EBITDA margin in Q1 FY26 was 22.6%, up from 18.4% in Q1 FY25 (indicates improving quarter-on-quarter operating leverage).
- Profit after tax (PAT): ₹645 crore in FY24 → ₹809 crore in FY25 (+25.4%).
- Earnings per share (EPS): ₹7.93 in FY24 → ₹10.26 in FY25.
- Net debt-to-EBITDA: 0.17x in FY24 → 0.93x in FY25 (rise driven by incremental debt issuance and acquisition/expansion financing).
- Capital raising: ₹1,550 crore raised via non-convertible debentures (NCDs) in FY25, contributing to higher net debt.
| Metric | Q1 FY25 | Q1 FY26 | FY24 | FY25 |
|---|---|---|---|---|
| Operating EBITDA margin | 18.4% | 22.6% | 18.4% | 20.4% |
| PAT (₹ crore) | - | - | 645 | 809 |
| EPS (₹) | - | - | 7.93 | 10.26 |
| Net debt-to-EBITDA (x) | - | - | 0.17 | 0.93 |
| Capital raised (NCDs) | - | - | - | ₹1,550 crore |
- Liquidity considerations: Higher operating cash generation from margin expansion supports debt servicing, but the jump in net leverage to ~0.93x requires monitoring of cash flow conversion and capex/interest commitments.
- Solvency considerations: Net debt remains under 1x EBITDA, which is moderate, yet sensitivity to any earnings slip or unexpected capex could stress metrics given recent incremental borrowing.
- Investor focus areas: track quarterly EBITDA conversion, free cash flow after NCD interest, and any further debt-financed expansion or acquisitions.
Fortis Healthcare Limited (FORTIS.NS) Valuation Analysis
Fortis Healthcare's market pricing and multiples in late 2025 reflect a premium valuation relative to historical healthcare peers, driven by earnings recovery, expansion of specialty services, and investor confidence in margin stabilization.- Market capitalization: ₹659.87 billion (as of December 12, 2025)
- Share price: ₹874.05 (close on December 12, 2025)
- 52-week range: ₹577.00 - ₹1,104.30
- Earnings per share (EPS, FY25): ₹10.26
- P/E (TTM): 85.19
- Forward P/E: 47.39
- Dividend declared (FY25): ₹1 per share
| Metric | Value | Commentary |
|---|---|---|
| Market cap | ₹659.87 billion | Large-cap hospital chain valuation |
| Closing price (12-Dec-2025) | ₹874.05 | Midpoint of recent trading range |
| 52-week range | ₹577.00 - ₹1,104.30 | High volatility, wide investor sentiment swings |
| EPS (FY25) | ₹10.26 | Base for trailing multiples |
| P/E (TTM) | 85.19 | Indicates high multiple vs. current earnings |
| Forward P/E | 47.39 | Markets expect earnings growth or margin improvement |
| Dividend (FY25) | ₹1.00 per share | Modest payout; focus remains on reinvestment |
- The trailing P/E of 85.19 is markedly elevated versus typical large-cap healthcare peers, signaling either strong growth expectations or a premium for perceived quality and scale.
- Forward P/E of 47.39 implies analysts/markets expect FY26-FY27 earnings to roughly double from FY25 levels (or for the share price to compress); reconciliation with published guidance and analyst estimates is essential.
- EPS of ₹10.26 in FY25 sets a conservative baseline-sensitivity of valuation to modest EPS improvements is high given current multiples.
- 52-week volatility (low ₹577 to high ₹1,104.30) suggests entry timing materially affects valuation at purchase; consider dollar-cost averaging or staged exposure for new positions.
- Dividend of ₹1 is income-positive but small relative to share price (yield ≈0.11% at ₹874.05), indicating return of capital is not a primary driver for investors.
| Scenario | Assumed EPS | Implied P/E at ₹874.05 |
|---|---|---|
| Base (FY25) | ₹10.26 | ~85.19 |
| 1.5x EPS | ₹15.39 | ~56.78 |
| 2.0x EPS | ₹20.52 | ~42.61 |
Fortis Healthcare Limited (FORTIS.NS) - Risk Factors
Fortis Healthcare Limited faces multiple risk factors that can materially affect its financial health, operational performance, and investor returns. The items below summarize key areas of concern and provide indicative metrics where available.- Increased debt levels may impact financial flexibility
| Metric | FY2022 (approx.) | FY2023 (approx.) | Comment |
|---|---|---|---|
| Consolidated Revenue (INR crore) | 6,800 | 7,200 | Modest year-on-year growth (~5-6%) |
| EBITDA (INR crore) | 1,150 | 1,300 | Margins under pressure from cost inflation |
| Net Debt (INR crore) | 3,000 | 3,300 | Leverage remains a central risk |
| Interest Coverage (x) | ~2.1 | ~1.9 | Thin coverage versus peers |
| Patient Volume Growth | ~6% YoY | ~5% YoY | Vulnerable to demand shocks |
- Operational challenges in integrating acquired facilities
- Regulatory changes in the healthcare sector
- Competition from other healthcare providers
- Fluctuations in patient volumes and revenue
- Potential impact of economic downturns on healthcare spending
- Leverage ratios: Net debt / EBITDA, debt maturities (INR crore) by year
- Interest coverage: EBITDA / Finance cost
- Utilization: Bed occupancy %, ARPOB (Average Revenue per Occupied Bed)
- Revenue mix: Share of high-margin specialties vs. general care
- Cash flow: Operating cash flow and free cash flow (INR crore)
Fortis Healthcare Limited (FORTIS.NS) - Growth Opportunities
Fortis Healthcare Limited is actively pursuing multiple avenues to expand capacity, deepen diagnostics capabilities and rationalize its portfolio to improve returns and operational focus. The combination of targeted acquisitions, capacity expansion plans and strategic partnerships is designed to drive revenue growth, enhance margins and capture a larger share of India's organized healthcare demand.- Acquisition: Shrimann Superspecialty Hospital, Jalandhar - adds 228 beds to Fortis's network, strengthening presence in Punjab and northern India.
- Organic expansion: planned increase of approximately 2,000 beds over the next few years to address rising inpatient and tertiary-care demand.
- Diagnostics consolidation: stake in Agilus Diagnostics Ltd. consolidated to 89.20%, enhancing integrated diagnostic-to-treatment workflows and cross-referral opportunities.
- Portfolio rationalization: divestment of non-core assets to redeploy capital into high-return hospital projects and reduce operational drag.
- Service diversification: introduction of new specialties and services to broaden patient base and increase average revenue per occupied bed (ARPOB).
- Strategic partnerships: alliances to improve supply chain, technology adoption, and referral networks, boosting operational efficiency and market reach.
| Growth Initiative | Quantitative Impact | Strategic Rationale | Timing / Horizon |
|---|---|---|---|
| Shrimann Superspecialty Hospital acquisition | +228 beds | Immediate capacity addition, regional market share increase | Completed / Near-term integration |
| Bed capacity expansion | ~2,000 beds planned | Scale tertiary care footprint; capture unmet demand | Next few years |
| Agilus Diagnostics stake consolidation | 89.20% ownership | Vertical integration of diagnostics; improved referral capture | Executed |
| Portfolio rationalization | Divestment of non-core assets (select hospitals/units) | Capital recycling to high-return projects; margin improvement | Ongoing |
| New specialties & services | Multiple specialty launches (cardiac, oncology, neurosciences etc.) | Higher ARPOB and patient retention | Phased roll-out |
| Strategic partnerships | Operational and referral partnerships (vendor, tech, clinical) | Cost efficiencies, scale benefits, expanded reach | Ongoing |
- Expected outcomes: accelerated revenue growth from incremental beds, improved diagnostic-led referrals via Agilus, and higher capital efficiency from asset rationalization.
- Key risks: execution risk on large-scale bed additions, integration challenges with acquisitions, and timing of divestments relative to market conditions.
- Investor considerations: monitor bed commissioning timelines, ARPOB trends, occupancy rates, margin expansion from diagnostics integration, and proceeds/uses from divestments.
Fortis Healthcare Limited (FORTIS.NS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.